Biotech

Biotech & Healthcare

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech

Top news of the week: 07.11.2022.

#WorldAntibioticAwarenessWeek
#AMR
#climatechange
#collaboration
#automimmunedisease
#clinicaltrial
#biotech

@jjfeds shared
On Nov 6, 2022
RT @healthcareandy: WSJ with the facts here: https://t.co/Rkrpvw6QuB
Open
Healthcare Stocks Offer Investors Refuge in Bruised Market

Healthcare Stocks Offer Investors Refuge in Bruised Market

The S&P 500’s healthcare sector index has outperformed the market by the widest margin since 2000.

@jonathanrockoff shared
On Nov 3, 2022
RT @matthewherper: A big one. I've been saying for a decade: "This is biology's century." And we're still not ready. My editors asked me to explain what that means. It was harder than I expected. I hope you like reading it. https://t.co/nMyL8crshw
Open
Here’s why we’re not prepared for the next wave of biotech innovation

Here’s why we’re not prepared for the next wave of biotech innovation

This is "biology's century," @matthewherper writes. But we’re approaching a moment when changes in what we understand are every bit as terrifying as exhilarating.

@BIODeutschland shared
On Nov 3, 2022
APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01 https://t.co/fUu4yQk3cx
Open
Press release: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01

Press release: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01

APEIRON Respiratory Therapies (AResT) announces positive results from Phase I trial of inhaled APN01 (alunacedase alfa, rhACE2).

@OHENews shared
On Nov 3, 2022
In the lead-up to #WorldAntibioticAwarenessWeek, our November Bulletin focuses on the silent & not-so-silent pandemics! From #AMR to #climatechange we are working to convene global partnerships & solutions w/ economic research & analysis at their core: https://t.co/aFp2VJxU2S https://t.co/MQhlxMrq7Y
Open
From silence to solutions: Tackling health care challenges together

From silence to solutions: Tackling health care challenges together

Declared by the World Health Organization as one of the top ten global public health threats facing humanity, the consequences of Antimicrobial Resistance (AMR) are set to be …

@MEDiSTRAVA_Cons shared
On Nov 3, 2022
Patient enrolment for Phase 2a #clinicaltrial of OSE-127/S95011, via a #collaboration agreement with @Servier and @OSEIMMUNO, has been completed for treatment in primary Sjögren’s syndrome. Read more in @Labiotech_eu: https://t.co/80oE1mLj1B #biotech #automimmunedisease
Open
Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

A phase 2a study is designed to evaluate the efficacy and tolerance of the monoclonal antibody OSE-127/S95011 in primary Sjögren’s syndrome.

Read more:
weekly 07.11.2022
View archives
Back to home

Subscribe to Biotech - Biotech & Healthcare.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech - Biotech & Healthcare.
Privacy Policy

Sign up for the weekly Biotech - Biotech & Healthcare newsletter

Never again miss anything or anyone that matter in Biotech

Sign up and receive the Biotech - Biotech & Healthcare weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy